Premium
Effective treatment and prevention of attempted suicide, anxiety, and aggressiveness with fluoxetine, despite proven use of androgenic anabolic steroids
Author(s) -
Amaral Julio M.X.,
Padilha Monica C.,
Chagas Silvana V.,
Baker Julien S.,
Mullen Carrie,
Vieira Neto Leonardo,
Aquino Neto Francisco R.,
Cruz Marcelo S.
Publication year - 2021
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.2912
Subject(s) - fluoxetine , anxiety , anabolism , suicidal ideation , depression (economics) , poison control , urinary system , medicine , psychiatry , anabolic androgenic steroids , anabolic agents , psychology , suicide prevention , serotonin , medical emergency , receptor , economics , macroeconomics
The treatment of a man who attempted suicide after experiencing symptoms of anxiety and aggressiveness associated with the use of androgenic‐anabolic steroids (AAS) is described. This report includes 30 days of inpatient treatment and a 6‐month follow‐up. Regular use of fluoxetine apparently prevented the onset of anxiety, depression, aggressiveness, and suicide ideation, even with the concurrent use of AAS. The urinary concentration of androgens, metabolites of AAS, and fluoxetine were monitored through analysis of urinary samples by the Brazilian Laboratory of Doping Control. Our results are congruent with previous findings describing the risk of suicide prompted by AAS use as well as the efficacy of fluoxetine in the treatment of mood disorders associated with the use of anabolic steroids.